Finance
Markets
No recent trading data. The last price we hold for GILD is from Jun 3 (48 days ago). This symbol may be delisted, renamed, or halted — the figures below reflect its last active session, not the current market.

GILD

stock Healthcare Drug Manufacturers - General
Gilead Sciences
$128.99 +1.42 (+1.11%) Delayed · quoted 47d ago
Healthy 74% Climbing

What the indicators say

Mixed 2 of 5 trend signals bullish
Momentum · RSI 14 Leaning bearish
42
0oversold 30overbought 70100

RSI 42 — soft momentum, not yet oversold.

EMA 21 $132.25
Below
Near-term trend is down
SMA 50 $134.54
Below
Medium-term trend is down
SMA 200 $128.81
Above
Long-term trend is up
50 / 200-day
Golden cross
50-day above the 200-day — bullish
Supertrend $137.84
Downtrend
Price is below the Supertrend band — bearish

A mechanical reading of the chart’s indicators — not investment advice.

Key statsas of Jun 3

The day open and close within the day's range
Low $127.50 High $129.86
Open
$128.99
+1.11%
Close
$128.99
+1.11%
52-week range where the price sits across its year
52w low $104.46 52w high $157.29
Current
$128.99
Prev close
$127.57
Volume 0.98× the 3-month average
0 avg 2× avg
Today
5.98M
3-mo avg
6.14M

Earningscalendar synced from Yahoo 57d ago

Most recent
May 775 days ago
Next expected
Aug 6in 16 days

Recent earnings dates

  • May 7 75 days ago
  • Feb 10 161 days ago
  • Oct 30, 2025 264 days ago
  • Aug 7, 2025 348 days ago

Past earnings dates come from GILD’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.

Fundamentalssynced from SEC 53d ago

Strong

Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), GILD’s fundamentals read as strong overall.

P/E ratio Strong
17.5x

At 17.5x, the price is a reasonable multiple of the company's annual profit.

Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.

Dividend yield Strong
2.45%

A 2.4% yield is a healthy, generally sustainable level of cash income.

The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.

Profit margin Strong
28.9%

A 28.9% margin is strong; the company keeps a healthy slice of every revenue dollar.

The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.

Return on equity Strong
37.5%

A 37.5% return on equity is strong; the company compounds owners' capital well.

Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.

Return on assets Strong
14.4%

A 14.4% return on assets is strong; the company squeezes good profit from its assets.

Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.

Debt-to-equity No data

Not enough data to compute debt-to-equity.

Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.

Current ratio Strong
1.55

At 1.55, short-term assets comfortably cover short-term bills.

Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.

Revenue growth Fair
+2.4%

Revenue grew 2.4% from the prior year: steady, modest expansion.

Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.

Earnings growth Strong
+1672.9%

Net income grew 1672.9% from the prior year: strong profit expansion.

Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.

Financialssynced from SEC 53d ago

FY2021FY2022FY2023FY2024FY2025
Revenue $27.3B$27.3B$27.1B$28.8B$29.4B
Net income $6.2B$4.6B$5.7B$480.0M$8.5B
Diluted EPS $4.93$3.64$4.50$0.38$6.78
Dividend / share $2.84$2.92$3.00$3.08$3.16
Total assets $68.0B$63.2B$62.1B$59.0B$59.0B
Total liabilities
Shareholder equity $21.1B$21.2B$22.7B$19.3B$22.7B

Leadershipsynced from SEC 59d ago

  • O'Day Daniel Patrick Chairman & CEO · Director
  • Dickinson Andrew D Chief Financial Officer
  • Berger Dietmar Chief Medical Officer
  • Burkhart Erin SVP, Controllership
  • Cain Wettan Keeley M EVP Gen Counsel, Legal & Comp
  • Mercier Johanna Chief Comm & Corp Aff Officer
  • Barton Jacqueline K Director
  • Bluestone Jeffrey Director
  • Horning Sandra Director
  • Kramer Kelly A. Director
  • Love Ted W Director
  • Manwani Harish Director
  • Rodriguez Javier Director
  • Welters Anthony Director

Officers and board are drawn from GILD’s recent SEC ownership filings (Forms 3, 4 and 5).

Notable recent eventspast year

Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.

Dividendssynced from Yahoo 52d ago

Pays quarterly Strong
2025 total
$3.16
2026 so far
$0.821 payment
2026 projected
$3.28+3.8% vs 2025

Projection scales GILD’s declared payments so far this year up to the inferred cadence, then compares to last year’s total. Between payouts it is an estimate, not a guarantee.

Payment history

  • Mar 13 $0.82
  • Dec 15, 2025 $0.79
  • Sep 15, 2025 $0.79
  • Jun 13, 2025 $0.79
  • Mar 14, 2025 $0.79
  • Dec 13, 2024 $0.77
  • Sep 13, 2024 $0.77
  • Jun 14, 2024 $0.77
  • Mar 14, 2024 $0.77
  • Dec 14, 2023 $0.75
  • Sep 14, 2023 $0.75
  • Jun 14, 2023 $0.75
  • Mar 14, 2023 $0.75
  • Dec 14, 2022 $0.73
  • Sep 14, 2022 $0.73
  • Jun 14, 2022 $0.73
  • Mar 14, 2022 $0.73
  • Dec 14, 2021 $0.71
  • Sep 14, 2021 $0.71
  • Jun 14, 2021 $0.71

Recent SEC filingssynced from SEC 53d ago